Takeda pares down products and jobs, revives Genzyme building plans

In a bid to downsize the debt it took on when buying Shire plc earlier this year, Takeda Pharmaceutical Co. Ltd. is shedding dozens of products and hundreds of employees in a $200 million deal. But the Japanese drugmaker is reviving plans to occupy Cambridge’s iconic Genzyme building.